Aldara (Imiquimod)
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Actinic Keratosis
Conditions
Actinic Keratosis
Trial Timeline
Feb 1, 2006 → Jan 1, 2007
NCT ID
NCT00294320About Aldara (Imiquimod)
Aldara (Imiquimod) is a phase 3 stage product being developed by Viatris for Actinic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00294320. Target conditions include Actinic Keratosis.
What happened to similar drugs?
7 of 20 similar drugs in Actinic Keratosis were approved
Approved (7) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00294320 | Phase 3 | Completed |
Competing Products
20 competing products in Actinic Keratosis